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Prolonged Survival in Patients with Lung Cancer with
Diabetes Mellitus
Peter Hatlen,*† Bjørn Henning Grønberg,‡§ Arnulf Langhammer, Sven M. Carlsen,¶#
and Tore Amundsen*†
Introduction: Patients with lung cancer have a high frequency of
comorbidity. Data on the impact of diabetes mellitus, the most
frequent endocrine disorder, on the prognosis of lung cancer are
conflicting. The aim was to investigate the impact of diabetes
mellitus on survival in lung cancer.
Method: We analyzed data from a cohort, the Nord-Trøndelag
Health Study (HUNT study) linked to the Norwegian Cancer Reg-
istry and controlled the results using two lung cancer studies, the
Pemetrexed Gemcitabine study and the Norwegian Lung Cancer
Biobank. Survival in lung cancer with and without diabetes mellitus
was compared using the Kaplan-Meier method and Cox regression
model for each study and the studies combined.
Results: One thousand six hundred seventy-seven cases of lung
cancer were included, 1031 from HUNT study, 436 from the
Pemetrexed Gemcitabine study, and 210 from the Norwegian Lung
Cancer Biobank registry, and among these 77 patients had diabetes
mellitus. In the combined analysis, patients with lung cancer with
diabetes mellitus had increased survival compared with those with-
out (p 0.005). The 1-, 2-, and 3-year survival in patients with lung
cancer with and without diabetes mellitus were 43% versus 28%,
19% versus 11%, and 3% versus 1%, respectively. Adjusting for
age, gender, histology, and stage of disease in the Cox regression
model, the hazard ratio for survival in patients with lung cancer with
diabetes mellitus was 0.55 (95% CI, 0.41–0.75) as compared with
without.
Conclusion: Patients with lung cancer with diabetes mellitus have
an increased survival compared with those without diabetes mellitus.
Key Words: Lung cancer, Diabetes mellitus, Survival.
(J Thorac Oncol. 2011;6: 1810–1817)
Lung cancer incidence is high in the western countries, andin Norway lung cancer ranks among all cancers as the
second highest in males and the third highest in females.1
Age, gender, tumor histology, stage of disease, and
performance status (PS) are well-established prognostic fac-
tors in lung cancer.2–5 Patients with lung cancer have a high
frequency of comorbidities. In clinical lung cancer studies,
patients with comorbidities often are excluded, leading to a
lack of information about the potential effect of comorbidity
on survival, quality of life, or the possible interactions of the
therapeutic agents on the comorbidity itself. One reason may
be that there is no consensus on how to assess comorbidity or
the impact of comorbidity on disease course or survival.6
Diabetes mellitus is the most prevalent endocrine dis-
order and the incidence is increasing. Results from studies on
the impact of diabetes mellitus on lung cancer prognosis are
to date conflicting. One report showed an increased survival,7
three authors referred no change in survival8–10 and two
studies showed decreased survival11,12 (Table 1). Diabetes
mellitus has been reported to be associated with increased
mortality in cancers of colon, pancreas, endometrium, liver,
and breast.13–16 Another concern is how targeted therapy like
insulin-like growth factor-1 receptor (IGF-1R) inhibitor may
influence the prognosis in patients with lung cancer with
diabetes mellitus. The aim of the present study was to analyze
the impact of diabetes mellitus on survival in patients with
lung cancer in a large Norwegian cohort study.
PATIENTS AND METHODS
The main study population was recruited from a pro-
spective cohort study, the Nord-Trøndelag Health study
(HUNT). In this population, we found 1206 cases of lung
cancer. Adding the 436 cases from the Pemetrexed Gemcit-
abine study (PEG study) and the 210 cases of lung cancer
from the Norwegian Lung Cancer Biobank study (NLCB
registry study), we identified a total of 1852 cases of lung
cancer that were evaluated for inclusion into our study.
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The aim of the study was to assess the influence of
diabetes mellitus on the mortality of lung cancer. Hence, we
included in the analyses only lung cancer-related mortality.
Additionally, in the 3-year follow-up period, 92% of all
patients who died, died of lung cancer-related mortality and
only 8% of other or unknown causes.
Study Populations
The HUNT study is a large population-based prospec-
tive cohort study in Norway having collected data in three
waves, HUNT 1 (1984–1986), HUNT 2 (1995–1997), and
HUNT 3 (2006–2008).17 Individuals aged 20 years or more
were invited each time. In total 77,216 (88% of invited),
65,215 (69% of invited), and 50,810 (54% of invited) people
participated in HUNT 1, 2, and 3, respectively. Many people
participated two or three times, which reduces the total
number of subjects to 106,456. Nord-Trøndelag is a county in
the middle of Norway having 130,708 inhabitants in January
2009. This population is considered representative of the
Norwegian population, but the county lacks larger cities, has
a lower educational and income level, and the proportion of
smokers is slightly below the mean in Norway.
In all of the study waves, data were collected from the
following three areas: demographic, personal and family
medical history, and clinical examinations. The control study
1 (the “PEG” study) was an open randomized multicenter
phase III trial of 436 patients with stage IIIB/IV non-small
cell lung cancer by the Norwegian Lung Cancer Group.18 The
aim of the study was to compare pemetrexed plus carboplatin
versus gemcitabine plus carboplatin as first line chemother-
apy, with respect to health-related quality of life, survival,
and toxicity. All patients received four cycles of chemother-
apy. The study was conducted from April 2005 to July 2006.
The control study 2 (NLCB, a registry study) started
March 15, 2006, and aims to collect tumor tissue, normal
tissue, and blood samples from patients consecutively admit-
ted to hospital and suspected to have lung cancer. Thus,
patient with and without lung cancer are included. In the
current study, we have only included patients with histolog-
ical verified lung cancer (stage of disease I-IV) until October
15, 2010.
Data from the HUNT study were linked to the Cancer
Registry of Norway and the Norwegian Cause of Death
Registry at Statistics Norway.19 In the PEG study and in the
NLCB registry, data were collected from the electronic pa-
tient records.
Patients with lung cancer were included, but if the
cause of death was either unknown (n  77) or other than
lung cancer (n 98), the patients were excluded. Six patients
of these 175 excluded patients with lung cancer had diabetes
mellitus.
Study Variables
Lung Cancer Diagnosis and Stage of Disease
Lung cancer diagnosis was based on traditional histo-
logical classification (World Health Organization. Histologi-
cal Typing of Lung Tumors, from the 2nd edition in 1981 to
date). Lung cancer was classified as non-small cell lung
cancer (NSCLC) or small cell lung cancer. Based on the
TNM classification system for lung cancer (International
Association for the Study of Lung Cancer, IASLC) the
Cancer Registry of Norway has categorized lung cancer into
nonmetastatic and metastatic disease for the whole period. No
tumor invasion of organ or neighbor structures, no lymph
node metastasis other than local lymph node metastasis was
defined as nonmetastatic disease. Patients with all other
metastatic features, including organ and lymph node metas-
tasis, were defined as metastatic disease.
We have no information about what treatment the
patients in the HUNT study and the NLCB registry received.
However, as in the PEG study where we have that informa-
tion, there are no recommendations in our guidelines indicat-
ing that patients with diabetes mellitus should be treated
differently from other patients.
Diabetes Mellitus
In the HUNT study, diabetes mellitus was defined by
the answer “yes” to the question “Do you have or have you
had diabetes.” Based on the age of the patients, use of
medication and the duration of diabetes mellitus, the majority
of the patients were classified as diabetes mellitus type 2. In
the PEG study and the NLCB registry, diabetes mellitus was
diagnosed according to information of diabetes mellitus
and/or the use of antidiabetic medication in the hospital
medical record.
Confounders
Gender, age (70 or 70 years), PS, stage of disease,
histology, and smoking status were tested in the regression
models. PS was accessible only for the PEG study. All except
for smoking contributed significantly and were included in
the models.
Statistical Analysis
All analyses were performed for each study and com-
bined to increase the power of the study. First, the Kaplan-
Meier method was used to compare the median overall
survival (OS) rate for patients with and without diabetes
mellitus, and we added the 1, 2, and 3-year survival rates in
both groups. Second, between groups differences in known
prognostic factors were tested with the 2 test. Third, when
the Log-rank test showed statistically significant differences,
we used the adjusted Cox regression model to adjust survival
for age, gender, tumor histology, and the stage of disease of
disease. In the PEG study, we adjusted also for PS. Hazard
ratio (HR) is reported with 95% confidence interval (CI), and
statistical significance was defined as p  0.05. Two-sided
test was used in all statistical procedures. Statistical analyses
were performed using PASW version 17 (Predictive Analyt-
ics Soft Ware IBM Corporation, New York, NY).
Ethical Considerations
The Regional Committee for Medical and Health Re-
search Ethics have approved both the current study (REK no.
2010/1081) and the two control studies.
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RESULTS
We analyzed the data from 1677 patients with lung
cancer (Figure 1). The number of patients with lung cancer in
the HUNT study, in the PEG study, and NLCB registry and
their demographical characteristics are given in Table 2.
Results from the Lung Cancer Population in
the HUNT Study
The Kaplan-Meier survival analysis showed a nonsig-
nificant trend toward increased survival in patients with lung
cancer with diabetes mellitus compared with those without
diabetes mellitus (p  0.077). Median OS was 8.0 months
(95% CI, 5.1–10.9) and 5.0 months (95% CI, 4.4–5.6),
respectively (Figure 2).
The 1, 2, and 3-year survival for patients with and
without diabetes mellitus were 33% versus 28%, 13% versus
8%, and 5% versus 1%, respectively. Patients with lung
cancer were equal in age (p  0.88), smoking history (p 
0.29), and tumor histology (p 0.48), although the frequency
FIGURE 1. Flow sheet of the number of eligible patients
included in the study.
FIGURE 2. Kaplan-Meier survival curve for patients with
and without diabetes mellitus in the HUNT study.
TABLE 2. Characteristics of Patients with Lung Cancer in the HUNT, PEG, and NLCB Study and These Cohorts When Merged
HUNT 1984–2008
(n  1206)
PEG 2005–2006
(n  436)
NLCB 2006–2010
(n  210)
Total
(n  1852)
DM
(n  49)
Non-DM
(n  1157)
DM
(n  17)
Non-DM
(n  419)
DM
(n  18)
Non-DM
(n  192)
DM
(n  84)
Non-DM
(n  1768)
n % N % N % N % N % N % N % n %
Age (yr)a 71.0  8.2 70  10.9 73  7.0 64  9.8 68  8.0 68  9.7 70.1  7.7 67.3  10.1
Gender
Male 39 80 749 65 12 70 239 57 10 56 112 58 61 73 1100 62
Female 10 20 408 35 5 30 180 43 8 44 80 42 23 27 668 38
Smoking history
Never 9 18 182 16 0 0 32 8 0 0 5 3 9 11 219 12
Ever 40 82 975 84 17 100 387 92 18 100 187 97 75 89 1549 88
Stage of disease
Non-metastatic 28 57 507 44 — — — — 8 44 80 42 36 43 587 33
Metastatic 11 22 520 45 17 100 419 100 9 50 110 57 37 44 1049 59
Unknown 10 21 130 11 — — — — 1 6 2 1 11 13 132 8
Histology
NSCLC 35 71 806 70 17 100 419 100 14 78 157 82 66 78 1382 78
SCLC 6 12 201 17 — — — — 3 17 27 14 9 11 228 13
Unknown 8 17 150 13 — — — — 1 5 8 4 9 11 158 9
n, number; HUNT, Health Study of Nord-Trøndelag; PEG, Pemetrexed Gemcitabine study; NLCB, Norwegian Lung Cancer Bio Bank; LC, lung cancer; DM, diabetes mellitus;
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
a Values given as median  SD.
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of males was higher (p  0.029) and the frequency of
metastatic disease was lower (p  0.011) among patients
with diabetes mellitus. In the Cox regression model, adjusting
for confounders, the nonsignificant trend of survival benefit
persisted (HR, 0.69; 95% CI, 0.46–1.04) (Table 3).
Results from the PEG Study
The Kaplan-Meier survival analysis showed an in-
creased 3-year survival in patients with lung cancer with
diabetes mellitus compared with those without diabetes mel-
litus (p  0.048). Median OS was 16.0 months (95% CI,
5.7–26.3) and 7.1 months (95% CI, 6.3–7.8), respectively
(Figure 3).
The 1-, 2-, and 3-year survival for patients with and
without diabetes mellitus were 53% versus 31%, 21% versus
12%, and 0% versus 0%, respectively. Patients with lung
cancer with and without diabetes mellitus were equal in age
(p  0.73), gender (p  0.27), smoking history (p  0.23),
and PS (p  0.453), whereas the frequency of metastatic
disease was lower (p  0.022) in the diabetes mellitus group.
Difference in histology could not be studied because all
patients in this study had NSCLC. In the adjusted Cox
regression model, diabetes mellitus showed increased sur-
vival in patients with lung cancer (HR, 0.51; 95% CI,
0.27–0.96).
When entering PS in the Cox model (together with age,
gender, and stage of lung cancer), diabetes mellitus remained
an independent prognostic factor for survival (HR, 0.48; 95%
CI, 0.25–0.91).
Results from the NLCB Registry
The Kaplan-Meier survival analysis showed equal
3-year survival in patients with and without diabetes mellitus
(p  0.93). Median OS was 14.0 months (95% CI, 8.2–19.8)
and 11.0 months (95% CI, 8.0–14.0), respectively (Figure 4).
The 1-, 2-, and 3-year survival for patients with and
without diabetes mellitus were 52% versus 53%, 31% versus
38% and 0% versus 29%, respectively. Patients with lung
cancer with and without diabetes mellitus were equal in age
(p  0.98), smoking history (p  0.49), gender (p  0.68),
stage of disease (p  0.64), and tumor histology (p  0.17).
In the Cox regression model, adjusting for confounders dia-
FIGURE 3. Kaplan-Meier survival curve for patients with
and without diabetes mellitus in the PEG study.
FIGURE 4. Kaplan-Meier survival curve for patients with
and without diabetes mellitus in the NLCB registry.
TABLE 3. Multivariate Analysis (Cox Regression) for Survival in Patients with Lung Cancer
HUNT PEG NLCB Total
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Age (70 yr vs. 70 yr) 1.47 1.27–1.69 0.001 1.05 0.84–1.31 0.652 1.62 1.12–2.36 0.011 1.39 1.24–1.56 0.001
Gender (male vs. female) 1.15 0.99–1.34 0.071 0.72 0.58–0.89 0.003 1.68 1.13–2.48 0.01 1.32 1.18–1.50 0.001
Stage of disease (metastatic
vs. non-metastatic)
1.85 1.59–2.15 0.001 1.22 0.96–1.55 0.102 2.94 1.92–4.49 0.001 1.67 1.47–1.89 0.001
Tumor histology (SCLC vs.
NSCLC)
1.05 0.89–1.25 0.54 — — — 0.92 0.71–1.18 0.512 1.33 1.14–1.55 0.001
DM vs. non-DM 0.69 0.46–1.04 0.08 0.51 0.27–0.96 0.037 0.74 0.38–1.44 0.381 0.55 0.41–0.75 0.001
All available known prognostic factors for survival in lung cancer where entered in the Cox-model.
HUNT, Health Study of Nord-Trøndelag; PEG, Pemetrexed Gemcitabine study; NLCB, Norwegian Lung Cancer Bio Bank; HR, hazard ratio; CI, confidence interval; LC, lung
cancer.
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betes mellitus was not significantly associated with survival
(HR, 0.74; 95% CI, 0.38–1.44).
Combined Survival Analysis in the HUNT and
PEG Study and NLCB Registry
The Kaplan-Meier survival analysis showed an in-
creased 3-year survival in patients with lung cancer with
diabetes mellitus compared with patients with lung cancer
without diabetes mellitus (p  0.005). Median OS was 10.0
months (95% CI, 7.7–12.3) compared with 6.0 months (95%
CI, 5.6–6.3) (Figure 5).
The 1-, 2-, and 3-year survival for patients with and
without diabetes mellitus were 43% versus 28%, 19% versus
11%, and 3% versus 1%, respectively. Patients with lung
cancer with and without diabetes mellitus were equal in age
(p  0.88), smoking history (p  0.92), and tumor histology
(p  0.88), whereas there were more males (p  0.048) and
lower stage of disease (p  0.034) among patients with
diabetes mellitus. In the Cox regression model, adjusting for
confounders, diabetes mellitus was an independent predictor
(HR, 0.55; 95% CI, 0.41–0.75) of increased survival in lung
cancer.
DISCUSSION
The HUNT study showed a trend toward increased
survival in patients with lung cancer with diabetes mellitus,
compared with patients without diabetes mellitus. In the PEG
study, but not in the NLCB study, we found a significant
survival benefit for those with diabetes mellitus. When pool-
ing the patients with lung cancer from all three study popu-
lations, increased OS was found in patients with lung cancer
with diabetes mellitus, both in the univariate and in the
multivariate analyses when adjusting for known prognostic
factors for survival among patients with lung cancer. Except
for gender and stage of disease, there was no imbalance in
other known prognostic factors between the two groups of
interest. The difference in stage-distribution is in our opinion
not the reason for this unexpected observation. Patients with
diabetes mellitus had longer survival also in the PEG study
that included only patients with advanced disease. In addi-
tion, the hazard ratio was consistent in all three studies, also
when adding PS in the analysis in the PEG study.
We found only one previous report showing increased
survival in patients with lung cancer and diabetes mellitus.7
This report did not adjust for confounders and the patient
number (lung cancer and diabetes mellitus) was as low as 25.
Thus, this report supports our outcome results, but the report
has obvious limitations that are also commented by others.9
Two studies reported decreased survival.11,12 The first study
was a recently published meta-analysis consisting of 97
studies including patients based on either increased fasting
blood glucose levels (7 mmol/l), medical records that
confirmed the use of antidiabetics, or the diagnosis of diabe-
tes mellitus. The mean age was about 55 years, compared
with a median age of 71 years of patients with lung cancer
reported by the National Cancer Institute,20 which is in
accordance with our study. The design and inclusion criteria
in The Emerging Risk Factors (TERF) Collaboration study
were different to our study. The diverging mean age, inclu-
sion criteria, and design may explain the different results and
the study populations and results are not directly comparable
with our study. The second study was a prospective study of
87 patients with advanced lung cancer, of them 11 patients
with diabetes mellitus, included over 1.5 years with 6 months
follow-up. There were 86% men, and no exact definition of
diabetes mellitus. The results were not adjusted for histology.
The fact that men were highly overrepresented and the lack of
precise definition of diabetes mellitus may explain the diverg-
ing results, compared with our study. A research letter, a
comment and reanalysis of a study and one study showed no
significant association between diabetes mellitus, lung can-
cer, and survival.8–10 However, despite no such association, it
is noteworthy that Hanbali et al., like we did, reported a lower
frequency of metastasis in lung cancer with diabetes mellitus.
Tammemagi et al.10 studied patients in a private health care
system using a retrospective design. Patients were either
black or white people and were included during a 3-year
period and were followed up for 2 more years. The Charlson
index of comorbidity was used and the authors performed the
same analyses as we did. Diabetes mellitus with end-organ
damage showed an elevated adjusted HR of 1.4 for survival
in patients with lung cancer and diabetes mellitus, but it was
not significant (95% CI, 0.2–2.72), as for diabetes mellitus
without end-organ damage.
All previous studies and reports are based on diverging
designs and/or a limited number of patients that may be the
cause of the inconsistent results (Table 1). With the introduc-
tion of individualized treatment using targeted therapy, co-
morbidity seems to be an important consideration. Reviewing
studies using IGF-1R antagonists have shown results that are
even more difficult to interpret.21 Serious adverse events such
as hyperglycemia and dehydration were seen in the patients
treated with IGF-1R antagonist (figitumumab).22,23 In addi-
tion, low body mass index and reduced creatinine clearance
FIGURE 5. Kaplan-Meier survival curve for patients with
and without diabetes mellitus in the HUNT and PEG study
and NLCB registry all combined.
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were predictive of early death for patients receiving figitu-
mumab plus chemotherapy versus only chemotherapy as
shown by Jassem et al. in an Abstract no. 7500 ASCO 2010.
This result underlines the importance of studying host-related
factors like comorbidity and the influence on the prognosis,
like serious adverse events related to the antitumor drug itself
or its impact on comorbidity. Like in this case, IGF-1R
antagonists may mask the positive prognostic effect of dia-
betes mellitus.
The fact that patients with diabetes mellitus showed a
lower frequency of metastatic diseases may partly explain the
survival benefit in patients with diabetes mellitus, because the
majority of the patients with lung cancer die of metastasis and
not of the primary tumor. However, as we adjusted for stage
of disease in our analyses this potential advantage can hardly
explain the observed increased survival in patients with
diabetes mellitus. In addition, increased survival in patients
with diabetes mellitus was clearly demonstrated in the PEG
study where all patients had advanced lung cancer.
It can be argued that the survival benefit seen in patients
with diabetes mellitus depends on more frequent and regular
consultations that lead to an earlier diagnosis and thereby a
survival benefit. However, the fact that the survival benefit
was even more pronounced among the patients in the PEG
study, where only patients with advanced lung cancer were
included, contradicts the view that frequent consultation as
the cause of increased survival.24 Most likely the majority of
the diabetic patients had diabetes mellitus type 2, so it is
unclear whether the result can be transferred to patients with
diabetes mellitus type 1.
The present study has some strengths and probably
advantages compared with the previous studies discussed
earlier. It is the first cohort study from a well-defined geo-
graphical area, with a stable and large number of inhabitants,
investigating lung cancer, diabetes mellitus, and survival. The
participation in the HUNT study was very high and indicates
that we have investigated a representative study population.
All previous studies are either clinical studies or letters or
reports that briefly described survival in patients with lung
cancer and diabetes mellitus, apart from the meta-analysis.11
In contrast to the previous studies, the present study included
patients with lung cancer without regard to histological clas-
sification or stage of disease, and that means minimal selec-
tion bias. Another advantage is the number of patients, 1600
patients with lung cancer without diabetes mellitus and 77
patients with lung cancer with diabetes mellitus.
In our study population (the HUNT study), the preva-
lence of lung cancer (1.9%), and diabetes mellitus (4%) is
comparable with what is seen in western countries. The
median age of the patients with lung cancer in the HUNT
study was 71 years and indicates good external validity of the
present study.
The three studies (HUNT, PEG, and NLCB study)
recruited patients from the same geographical part in Norway
(North or South Trøndelag in the middle of Norway). They
represent different time periods, and the HUNT and the
NLCB study included all diagnosed patients with lung can-
cer, whereas the PEG study included only advanced NSCLC
(IIIB/IV). Thus, these patients are hardly highly selected.
A potential shortcoming is that we had no exact infor-
mation about treatment in the HUNT study. On the other
hand, we have no reason to believe that the treatment indi-
cation and chosen therapy for lung cancer in the three studies
differ between patients with and without diabetes mellitus
during the study period. In Norway, we practice very similar
treatment indications and treatment modalities for the lung
cancer population in accordance to the national guidelines,
both with and without diabetes mellitus. In sum, we have
found a rather consistent pattern with increased survival in
patients with lung cancer with diabetes mellitus compared
with those without diabetes mellitus.
CONCLUSION
In the patients with lung cancer, diabetes mellitus
associates with increased survival compared with patients
without diabetes mellitus. Standard therapy should not be
withheld from patients with diabetes mellitus provided they
are otherwise fit: even if it may be considered a significant
comorbidity. The survival benefit may be of clinical impor-
tance and should be focused on in future studies.
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